Efforts Underway To Lower Cost Of New Hepatitis C Drug

Two Reuters articles discuss efforts to lower the cost of a new hepatitis C treatment.

Reuters: Gilead aims to license hepatitis C drug to 3-4 Indian firms
“Gilead Sciences aims to license its new hepatitis C drug Sovaldi to three or four Indian generic manufacturers to allow sales of the medicine at lower prices in some 60 developing nations…” (Hirschler, 4/8).

Reuters: WHO joins clamor to make new hepatitis C pills affordable
“The World Health Organization wants a ‘concerted effort’ to drive down the cost of new hepatitis C drugs that offer a cure for the liver-destroying virus but are unaffordable for most infected people worldwide…” (Hirschler, 4/9).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.